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ABSTRACT 
The Leahy-Smith America Invents Act of 2011 (AIA) 
makes fundamental changes to the legislative landscape 
governing patent law in the United States and will bring 
about corresponding changes in the manner in which 
inventors and attorneys address patent issues. While the 
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law is newly implemented, inventors in all sectors of the 
economy are eager to formulate reactions to it. In this 
Article, we explore the effects of the AIA on nonprofit 
research organizations dedicated to global health and life 
sciences. We report the perspectives of counsel 
representing such organizations throughout the Pacific 
Northwest. We also consider the patent system, and the 
Act’s effects on the system, in the context of scientific and 
humanitarian motivations. 
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INTRODUCTION 
 
Imagine the following scenario: A technology manager at a 
nonprofit bioscience research organization contacts her 
institution’s patent counsel, excited to share an extremely 
promising advance from one of her labs—a new adjuvant system 
that greatly increases the efficacy of a developmental tuberculosis 
vaccine. The system works so well that she is certain that a large 
pharmaceutical company will pay a significant licensing fee for the 
technology. All that is needed, she thinks, is to file a patent 
application to protect the invention and help secure the funding 
required to deliver a new vaccine system to at-risk populations 
around the world. Additionally, this deal will provide crucial 
funding for the organization in a difficult economy. 
Tragically, the benefits of this invention may not be realized. 
The researcher who developed the new system neglected to inform 
the technology manager about a symposium presentation during 
the invention’s early stages, about a year ago. Cognizant of the 
existing patent laws, he did not distribute any printed publications 
regarding his invention, but a slideshow featuring his abstract was 
accessible on the symposium website for an undetermined length 
of time. Under the newly implemented America Invents Act 
(AIA), the invention may be considered available to the public for 
over a year and therefore not patentable. As a consequence of 
failing to file an application until after March 16, 2013, the 
nonprofit organization could lose out to a wealthier applicant—
perhaps its potential licensee—under the new “first-inventor-to-
file” priority system. With no patent to protect its intellectual 
property, the nonprofit loses control over a licensable technology, 
cannot attract investment to develop or deliver the adjuvant where 
it will do the most good, and loses a valuable source of revenue. 
This hypothetical, while somewhat simplistic and dramatic, 
illustrates the potential impact of the AIA on inventors in the 
nonprofit sectors.  
Part I of this Article discusses the statutory and historical 
backdrop of both the U.S. patent system and the AIA. Part II 
examines nonprofit research organizations as innovators within the 
patent system and describes our inquiry into the AIA’s effects—
3
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real, perceived, or anticipated—on these innovators. This inquiry 
focuses on five aspects of the AIA that we identified as being of 
special concern to nonprofits. In Part III, we discuss the results of 
our qualitative survey on the aforementioned effects of the AIA on 
nonprofit innovators, as described by the in-house and outside 
counsel who represent such innovators in the Pacific Northwest.  
 
I. THE U.S. PATENT SYSTEM AND THE AMERICAN INVENTS ACT 
 
A.  Innovation and the U.S. Patent System  
 
Innovation has been celebrated in the United States since the 
Founding. It has been called “the key driver of competitiveness, 
wage and job growth, and long-term economic growth,”1 and this 
valuation has resulted in an advanced system of intellectual 
property laws designed to foster innovation, as a mechanism for 
advancing society, by rewarding individual efforts. 
In that spirit, the drafters of the Constitution empowered 
Congress “[t]o promote the Progress of Science and useful Arts, by 
securing for limited Times to Authors and Inventors the exclusive 
Right to their respective Writings and Discoveries.”2 The resulting 
intellectual property laws enacted by Congress protect exclusive 
rights that are expressed in copyright,3 trademarks,4 and patents. A 
patent is an exclusive government-granted exclusive right to make, 
use, sell, or offer to sell a claimed invention for a limited time.5 
The rightful holder of a patent is empowered to sell or license the 
patent, or to sue for damages or an injunction when the right is 
infringed. For a patent to issue, the invention must meet certain 
utility, novelty, and nonobviousness requirements as determined 
1 U.S. Dep’t of Commerce, The Competitiveness and Innovative Capacity 
of the United States (Jan. 2012) at 9, http://www.commerce.gov/sites/ 
default/files/documents/2012/january/competes_010511_0.pdf. 
2 U.S. CONST. art.1, § 8, cl. 8. 
3 See 17 U.S.C. § 102(a) (2006) (copyright given to the author of original 
works that are fixed and reproducible). 
4 See 15 U.S.C. § 1127 (2006) (trademark protects a “word, name, symbol, 
or device” identifying unique goods). 
5 AMY L. LANDERS, UNDERSTANDING PATENT LAW 1 (LexisNexis, 2nd ed. 
2012) (defining “practicing” a patent). 
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by an examiner at the United States Patent and Trademark Office 
(USPTO).6 A patent application to the USPTO must also contain 
“one or more claims particularly pointing out and distinctly 
claiming the subject matter which the inventor or joint inventor 
regards as the invention.”7 Claims define the patented invention 
and determine its operative legal effect.8 If a patent issues, the 
holder obtains an exclusive right to the invention for twenty years 
from the initial filing date of the application. 
In a global marketplace, the value of exclusive rights to an 
invention is potentially massive. A recent study showed that the 
2,000 largest global companies invested more than $640 billion in 
research and development in 2008.9 In the United States, the 
number of patents issued annually has increased from roughly 
70,000 in the 1980s to well over 200,000 in the 2000s, with over 8 
million total patents issued since the late eighteenth century.10 In 
the short term, this trend looks set to continue.11 
6 A patentable invention is one that is truly novel, provides a function, and 
is not obvious, in light of previous knowledge, to an inventor of ordinary skill in 
the art. See U.S. Patent and Trademark Office (USPTO), Novelty and 
Nonobviousness, Conditions for Obtaining a Patent (Nov. 2011), 
http://www.uspto.gov/ 
patents/resources/general_info_concerning_patents.jsp#heading-5. See also 35 
U.S.C. § 112(a) (requiring a “written description of the invention, and of the 
manner and process of making and using it, in such full, clear, concise, and 
exact terms as to enable any person skilled in the art to which it pertains”) 
(emphasis added). 
7 35 U.S.C. § 112(b) (2006).  
8 LANDERS, supra note 5, at 57.  
9 Joint Research Centre (EC), INSTITUTE FOR PROSPECTIVE 
TECHNOLOGICAL STUDIES, The 2009 EU Industrial R&D Investment 
Scoreboard, at 16, (2009), http://iri.jrc.ec.europa.eu/scoreboard09. 
html;jsessionid=py3jSywRGLKbzyBl4vrGv452FddZzjW9D9FdT7ysvyDnyRL
gljpX!-573964881!1390997617993. We converted the figure from euros to U.S. 
dollars using the average conversion value for the year 2008, calculated using 
data from X-Rates, available at http://www.x-rates.com/average/ 
?from=EUR&to=USD&amount=1.00&year=2008. 
10 USPTO, U.S. Patent Activity, Calendar Years 1790 to the Present. 
http://www.uspto.gov/web/offices/ac/ido/oeip/taf/h_counts.htm (last visited Feb. 
6, 2014).  
11 See Dennis Crouch, USPTO Grant Rate: 2013 Forecast, PATENTLYO 
(Jan. 8, 2013, 11:19 AM), http://www.patentlyo.com/patent/2013/01/uspto-
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B.  Legislative Background and Context 
 
As patent activity in the United States has grown in scope and 
intensity, evolution has been necessary to achieve positive societal 
outcomes through a system predicated on private incentives. Since 
the Patent Act of 1790, the system has undergone continual 
amendment, with the last major changes made in 1952.12 Recently, 
commentators have cited the high costs of litigation, common 
abuses of the patent system,13 and the divide between U.S. and 
foreign practices to justify further legislative address.14 
To that end, some legislators attempted revisions via the 
proposed Patent Reform Acts of 2005, 2007, and 2009. Various 
provisions in these bills attempted to decrease the overall costs and 
sheer amount of patent litigation while raising the quality, 
efficiency, and international compatibility of the patent system.15 
However, it was not until January 2011 that Senators Patrick 
Leahy of Vermont and Lamar Smith of Texas co-sponsored a 
successful bill, enacted as the AIA in September of that year.16 The 
AIA’s central provisions took effect on March 16, 2013. 
Given its economic significance, the bill was unsurprisingly 
grant-rate-2013-forecast.html (stating that the USPTO, shortly after issuing a 
single-day record of 5,633 utility patents on Jan. 8, 2013, projects issuing a 
record 290,000 patents this year).  
12 US Patents—A Brief History, THE BUSINESS OF PATENTS (Feb 7, 2014), 
http://www.the-business-of-patents.com/us-patents.html. 
13 One common complaint among small inventors is that frivolous lawsuits 
filed by larger entities (often non-practicing entities or “patent trolls”) stifle 
innovative progress because inventors spend valuable resources defending 
against the claim that would be better spent on R&D. See Ben Lee, Twitter: It’s 
time for patent trolls to bear the cost of frivolous lawsuits, GIGAOM (Oct. 8, 
2012, 6:00 AM), http://gigaom.com/2012/10/08/twitter-time-for-trolls-to-pay-
full-price-for-patent-mischief. See also Charles Duhigg and Steve Lohr, The 
Patent, Used as a Sword, N.Y. TIMES (Oct. 7, 2012), 
http://www.nytimes.com/2012/10/08/technology/patent-wars-among-tech-
giants-can-stifle-competition.html?pagewanted=all. 
14 Jason Rantanen, Lee Petherbridge & Jay P. Kesan, America Invents, 
More or Less?, 160 U. PA. L. REV. 229 (2012). 
15 Patent Reform Act of 2009, GOVTRACK.US, https://www.govtrack.us 
/congress/bills/111/s515#summary (last visited Feb. 3, 2014). 
16 See A Companion to Science and Engineering Indicators 2008, NAT’L 
SCIENCE BD. (Jan. 2008), http://www.nsf.gov/statistics/nsb0803/start.htm. 
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subject to intense lobbying efforts as it wound its way through 
Congress. Large corporations in the financial services, 
pharmaceutical, and computer/telecommunications industries were 
strong proponents of the proposed AIA. Notably in favor were 
such established entities as Microsoft, IBM, GE, Caterpillar, Dow 
Chemical, PepsiCo, and Procter & Gamble.17 Newer technology 
industry actors, including Google, Apple, Yahoo!, and eBay 
favored the move to “first-to-file” but disapproved of the proposed 
legislation because they feared it would raise the costs of the patent 
challenge system, ultimately detracting from valuable research and 
development (R&D) efforts.18 
In notable opposition to the AIA, the National Small Business 
Association (NSBA) claimed that the law was severely tilted 
“against small innovators and in the favor of large, multinational 
corporations.”19 According to the NSBA, small entities are the 
most efficient drivers of the patent system, but are greatly 
disadvantaged under a first-to-file regime, which favors large 
companies that can quickly file fully developed applications.20 
Many commentators shared this concern.21 Further, the NSBA 
interpreted the AIA to “gut” a one-year grace period prior to filing 
a patent application, during which inventors could raise capital and 
create partnerships without fear that disclosures would become 
prior art.22 Thus, some tension existed between small and big 
17 See Kurt Mackie, Q&A: A Patent Attorney Explains How the ‘America 
Invents Act’ Will Affect Tech, REDMOND MAGAZINE (Sep. 20, 2011), available 
at http://redmondmag.com/articles/2011/09/20/impact-of-america-invents-on-
tech.aspx.  
18 Id. 
19 Nat’l Small Bus. Ass’n, NSBA Cautions Lawmakers Against Patent 
Reform, (Sep. 7, 2011) http://www.nsba.biz/content/4181.shtml. 
20 Nat’l Small Bus. Ass’n, Patent Reform: Small business concerns are 
fundamental to any discussion concerning patent reform (May 2012), 
http://www.nsba.biz/wp-content/uploads/2012/05/Patent-Reform.pdf.  
21 See, e.g., Clyde Prestowitz, The Prevent American Invention Act, 
FOREIGN POLICY (May 16, 2011), available at 
http://prestowitz.foreignpolicy.com/posts/2011/05/16/the_prevent_american_inv
ention_act. 
22 Nat’l Small Bus. Ass’n, Patent Reform Bill Will Crush Small-Business 
Innovation, NSBA LATEST NEWS (June 22, 2011), 
http://www.nsba.biz/content/4008.shtml. 
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business with respect to the AIA. The perspective the academic 
and nonprofit sectors, another significant innovating community, 
did not receive as much attention.  
 
II. THE POTENTIAL IMPACT OF THE AIA ON  
NONPROFIT INNOVATION 
 
Nonprofit innovators at government entities, independent 
research centers, foundations, hospitals, and universities operate 
under much different circumstances—and often with quite 
different goals—than their counterparts in the for-profit world. 
From bone marrow transplants to satellite communication, 
nonprofit entities have made significant inventive contributions to 
many vital technological fields.23 If applying technology to solve 
compelling problems is a desired outcome of the patent system, 
then any assessment of that system must consider the state of 
medicine and public health. 
While for-profit companies typically mass-produce and bring 
therapeutics to the commercial market, most of the basic research 
advancing health science in this country is conducted at publicly 
funded universities and other nonprofit research centers.24 These 
23 For example, the first successful bone marrow transplant was conducted 
at the Fred Hutchinson Cancer Research Center by Dr. E. Donnell Thomas in 
1956, see Fred Hutchinson Cancer Research Ctr., Impact of Dr. E. Donnall 
Thomas’s Work, http://www.fhcrc.org/en/about/honors-awards/nobel-
laureates/thomas/thomas-impact.html (last accessed Mar. 30, 2013), while work 
at the National Aeronautics and Space Administration (NASA) has produced or 
led to such advances as water filters, adjustable smoke alarms, cochlear 
implants, insulin pumps, arterial imaging technology, and major advances in 
long-distance telecommunications. See, e.g., Patrick J. Kiger and Marianne 
English, Top 10 NASA Inventions, HOWSTUFFWORKS, 
http://www.howstuffworks.com/innovation/inventions/top-5-nasa-
inventions.htm#page=3 (last accessed Apr. 4, 2013). 
24 See Nat’l Sci. Found., A Companion to Science and Engineering 
Indicators 2008, (Jan., 2008), http://www.nsf.gov/statistics/nsb0803/start.htm 
(“Federal funding is the primary source of basic research support in the U.S. 
(over 59% in 2006), of which about 56% is carried out by academic institutions. 
U.S. basic research is also funded by foundations (about 10%), universities and 
colleges (about 10%), and state and local governments (about 3.5% through 
funding of academic basic research”)). 
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research institutions make notable contributions to economic 
activity25 and play a major role in commercializing early-stage 
inventions.26 Although nonprofit organizations freely disseminate 
much of their work for the benefit of the public, substantial 
benefits can be realized when discoveries from nonprofit research 
enter the commercial sector for development into useful products 
and processes. The landmark 1980 Bayh-Dole Act27 has been an 
extraordinarily successful mechanism for facilitating the transfer of 
basic discoveries into the commercial sector for development.28  
The general goals of nonprofit research institutions are to 
increase the scope of knowledge in relevant fields; publish findings 
25 Nonprofit research organizations have contributed between $199-$836 
billion of U.S. gross domestic product from 1996-2010. See Lori Pressman et 
al., The Economic Contribution of University/Nonprofit Inventions in the United 
States: 1996-2010, BIOTECHNOLOGY IND. ORG. (June 20, 2012), 
http://www.bio.org/sites/default/files/BIOEconomicImpact2012June20.pdf.  
26 Frank X. Curci, Life Sciences: Changes in patent law challenge nonprofit 
bioscience institutions, PUGET SOUND BUS. J., July 13, 2012, 
http://www.bizjournals.com/seattle/print-edition/2012/07/13/life-sciences-
changes-in-patent-law.html?page=all. 
27 Pub. L. 96-517 (authorizing universities and small businesses to retain 
patent and licensing rights to inventions resulting from federally funded research 
and requiring recipients of federal funds “to maximize the use of their research 
findings by making them available to the research community and the public at 
large and through their timely and effective transfer to industry for 
development.”). See also NATIONAL INSTITUTES OF HEALTH, Developing 
Sponsored Research Agreements: Considerations for Recipients of NIH 
Research Grants and Contracts. 59 Fed. Reg. 55673, 55674–79, Nov. 8, 1994, 
available at http://grants.nih.gov/grants/guide/notice-files/not94-213.html (last 
accessed Feb. 7, 2013).  
28 See Memorandum from the Ass’n of Am. Univ. et al. to Office of Sci.and 
Tech. Policy and Nat’l Econ. Council on Commercialization of Univ. Research 
(May 10, 2010), available at http://www.aau.edu/WorkArea/ 
DownloadAsset.aspx?id=10808 (noting that prior to 1981 fewer than 250 
patents were issued to United States universities annually, and laboratory 
discoveries were seldom commercialized for the public benefit). See also 
Association of University Technology Managers U.S. Licensing Activity Survey 
Highlights (2011), http://www.autm.net/AM/Template.cfm?Section=FY_2011_ 
Licensing_Activity_Survey&Template=/CM/ContentDisplay.cfm&ContentID=
8731 (finding that 4,700 United States patents were issued to United States 
universities during 2011, while 671 new start-up companies were formed and 
591 new products were introduced based upon university inventions). 
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and secure further funding; and, depending on the institution, 
implement the findings to solve the problem. The governing 
objective for many nonprofit health science organizations is to 
treat or eradicate diseases such as cancer, tuberculosis, or malaria 
through therapeutics, vaccines, public health mechanisms, or other 
means. The nonprofit model subsumes economic gain to problem-
solving goals. Nonetheless, licensing technology plays an 
important role in the nonprofit sector because licensing technology 
to commercial actors for development and introduction to market 
is mutually beneficial for both nonprofit and commercial actors. 
Patents are critical to enabling this process. Identifying, 
cultivating, and selling commercially successful health science 
products is an extremely expensive and risky process29 involving 
numerous failed candidates and experimental setbacks.30 For a 
nonprofit to realize the promise of a given innovation, it must be 
marketed to commercial partners as a viable, low-risk investment. 
The security of the innovation’s intellectual property mitigates the 
risk of an investment. Nonprofits, therefore, are motivated to 
protect their intellectual property. 
Other features of nonprofit bioscience research organizations 
distinguish them from similar innovating communities as well. 
While curing a certain disease may be a nonprofit research 
organization’s mission, innovation in furtherance of that mission is 
largely practiced by academic scientists, whose individual aims 
may diverge from those of the parent organization. The time a 
researcher spends with a given organization may be relatively short 
(graduate or fellowship tenures often range from three to six 
29 The average input cost for a commercially available drug is in excess of 
$1 billion. See Roger Collier, Drug development costs hard to swallow, CAN. 
MED. ASS’N. JOURNAL (Feb. 3, 2009), available at 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630351/pdf/20090203s00009p
279.pdf. 
30 More than 6,000 completely new chemical compounds are synthesized 
for every one drug that ultimately comes to market. See Gregory A. Petsko, 
When failure should be the option, BIOMEDCENTRAL (May 21, 2010), 
http://www.biomedcentral.com/1741-7007/8/61. See also Sandra Krajlevic, 
Peter J. Stambrook & Kresimir Pavelic, Accelerating drug discovery, EMBO 
REPORTS (Sept. 2004), http://www.ncbi.nlm.nih.gov/pmc/articles/ 
PMC1299137. 
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years). In that context, these scientists are incentivized to publish 
their work as a primary goal. Disclosing a promising development 
can enhance a researcher’s career and advance scientific 
knowledge. Thus, most researchers are not as concerned with 
exploring commercial opportunities as they are with producing 
quality research and securing research funding.31 
As such, the major aims of the innovators and the nonprofit 
research entity they innovate “for” are sometimes imperfectly 
matched. These factors, in the context of commercial and legal 
realities, create a unique set of considerations regarding intellectual 
property protection. The leadership and administration of such 
organizations, as well as the attorneys who counsel them, must 
assess intellectual property practices against the nonprofits’ goals 
and limited resources.32 A high concentration of nonprofit research 
31 This assertion is based on the Authors’ respective experiences in 
academic science and the opinions of our survey respondents. 
32 A complete exploration of the patent system and its role in promoting 
positive advances necessarily encompasses an examination and critique of 
whether patents are a necessary or even desirable way to spur innovation. This 
Article assumes that patent law is a fixed construct in our social landscape, and 
that it does provide certain benefits and incentives to innovators across the for-
profit and nonprofit spectrum. Our scope is accordingly limited to how 
nonprofits can best operate and how systemic changes affect nonprofit research. 
However, there are certainly examples of unpatented biotechnology benefitting 
the world (e.g., the polio vaccine was never patented), and many serious 
criticisms of the patent system exist. Critics claim, for example, that patents 
reward the already wealthy, monopoly slows innovation and worthy uses of 
technology, bad patents on already-known inventions are commonly issued, 
patents permit non-practicing entities to depress the efficacy and affordability of 
using technology, patents on human genes or food products are unfavorable for 
a number of reasons, patents reward only incremental improvements in 
pharmaceutical products, rather than actually solving health problems, and that 
such patents raise drug costs to prohibitive levels, depriving the poor from that 
benefit and enriching shareholders in large pharmaceutical companies. See 
generally Richard A. Posner, Why There Are Too Many Patents In America, 
THE ATLANTIC (July 12, 2012), http://www.theatlantic.com/business/archive/ 
2012/07/why-there-are-too-many-patents-in-america/259725/.  
Inventors may choose alternatives to patenting, such as publishing 
defensively to prevent a patent by another and providing the invention freely to 
the world, providing federal “prize money” to compensate inventors for 
forgoing a patent monopoly, pursuing exclusive licenses to ensure that 
customers do not use a competing product but permitting others to use the idea, 
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and funding organizations is found in the Pacific Northwest,33 
including the Bill & Melinda Gates Foundation, the University of 
Washington, Fred Hutchinson Cancer Research Center, the 
Infectious Disease Research Institute, Washington State 
University, Seattle Biomedical Research Institution, PATH, Seattle 
Children’s Research Hospital, Oregon Health Sciences University, 
and the Institute for Systems Biology. These entities focus on 
advancing science and solving worldwide public health issues. 
To create our survey, we identified five aspects of the AIA 
likely to most impact these and similar nonprofit research 
organizations: (i) The transition from a “first-to-invent” to a “first-
inventor-to-file” (FITF) system, (ii) the prior commercial use 
defense to infringement claims and accompanying university 
exception, (iii) the expanded definition of prior art and changes to 
the inventor’s one-year pre-filing grace period, (iv) the amended 
third party patent challenge system, and (v) the implementation of 
derivation proceedings and new post-grant challenge procedures. 
We will present each of these aspects of the AIA before discussing 
the survey response data.  
 
A.  First-Inventor-to-File 
 
Among the most significant changes under the AIA is a shift 
from a first-to-invent system to an FITF system, which went into 
effect on March 16, 2013.34 Prior to the AIA, the United States 
issued patents based on a first-to-invent system, whereby patent 
priority went to the first inventor in fact, rather than to the first 
inventor to file for a patent.35 In contrast, the AIA awards patent 
and implementing “utility models,” which have a shorter duration and are 
cheaper and easier to obtain. See, e.g., World Intellectual Prop. Org., Protecting 
Innovations by Utility Models, http://www.wipo.int/sme/en/ip_business/ 
utility_models/utility_models.htm (last visited Feb. 6, 2014).  
33 A recent tally listed over 40 biology focused nonprofits, academic 
institutions, and support organizations in the region. See Stewart Lyman, Seattle 
(NW) Biotechnology Resource Page, LYMAN BIOPHARMA CONSULTING LLC, 
http://www.lymanbiopharma.com/seattlebionon-profits.html (last visited Feb. 6, 
2014).  
34 H.R. 1249 § 3(b), 112th Cong. (2011). 
35 35 U.S.C § 102(g) (1952). 
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rights to the first inventor to file, thereby placing a premium on 
filing as soon as possible. Whether the first applicant actually 
represents the first completion of the invention is irrelevant.36 This 
system comports with similar first-to-file patent systems in most 
other countries.  
International harmonization was a key goal of the AIA, but the 
United States’ FITF system is discernible from the traditional 
international first-to-file system.37 Under a traditional first-to-file 
system, absolute novelty is required in order to obtain a patent; that 
is, no patent can be granted if there is a prior use or publication of 
information relating to the invention.38 By contrast, the AIA 
maintains a one-year grace period, dating back from the inventor’s 
filing date, wherein certain disclosures of the invention will not bar 
patentability. This grace period has been modified and is addressed 
in Part II(d).  
In addition, the “effective filing date” under the AIA is either 
the actual filing date of the nonprovisional application or the filing 
date of the provisional application that the applicant is entitled to 
claim.39 While a provisional application cannot result in a patent, 
under a relation-back theory, the application gives a later  
 
36 Wendy H. Schact & John R. Thomas, The Leahy-Smith America Invents 
Act: Innovation Issues, Cong. Research Serv., C.R.S. R4201 (2013), available at 
https://www.fas.org/sgp/crs/misc/R42014.pdf. 
37 Wendell Ray Guffey & Kimberly Schreiber, America Invents Act: The 
Switch to a First-to-File, 68 J. Mo. B. 156 (2012), available at 
http://www.mobar.org/uploadedFiles/Home/Publications/Journal/2012/05-
06/invents-act.pdf. 
38 See Gene Quinn, America Invents: A Simple Guide to Patent Reform, 
Part 1, IPWATCHDOG (January 9, 2013, 12:30 PM), 
http://www.ipwatchdog.com/2011/09/26/america-invents-a-simple-guide-to-
patent-reform-part-1/id=19427/. 
39 The various circumstances that can determine the appropriate filing date 
are described in under 35 U.S.C. §§ 119, 120, 121, or 365(a)-(c). H.R. 1249 §3 
(2011). A provisional application must include a specification and drawing, but 
does not need to include a claim. See 35 U.S.C. § 111(b) (2011). In contrast, a 
nonprovisional application must include a specification, a drawing, and an oath 
and be accompanied by the appropriate fee and signed by the inventor. 35 
U.S.C. § 111. The specification of a nonprovisional must include one or more 
distinct claims about the invention. 35 U.S.C. § 112(b) (2011). 
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nonprovisional application the benefit of the provisional filing date 
for priority purposes.  
 
B.  Prior Commercial Use and the University Exception 
 
Predating the AIA, the American Inventors Protection Act of 
1999 provided a “prior commercial use” defense against 
infringement claims for commercial users of a “method of doing or 
conducting business” that was later patented by another.40 If a 
company retained an invention as a trade secret,41 and a competitor 
later created and patented the invention, the first company would 
be able to raise the prior commercial use defense against an 
infringement claim and thus continue using the method. Without 
this defense, a trade secret owner accused of infringement would 
have to choose whether to pay a licensing fee to the patent holder 
or pursue litigation to invalidate the patent. 
The AIA expands the prior commercial use defense beyond the 
scope of business method patents to include any type of 
invention.42 That is, the defense is now available to persons who 
independently employed the invention in the United States in 
connection with an internal commercial use, an arm’s length sale, 
or an arm’s length transfer of a useful end result of the commercial 
use.43 This defense, however, is subject to limitations and 
exceptions. It is personal and may not be licensed, assigned, or 
40 USPTO, Report on the Prior User Rights Defense, Report to Congress at 
6 (2012), available at http://www.uspto.gov/aia_implementation/20120113-
pur_report.pdf  
41 Trade secret law is concerned with the protection of technological and 
commercial information that is not generally known in the trade against 
unauthorized commercial use by others. See Kewanee Oil Co. v. Bicron Corp., 
416 U.S. 470, 473 (1990) (“The subject of a trade secret must be secret, and 
must not be of public knowledge or of a general knowledge in the trade or 
business.”). 
42 35 U.S.C. § 273(a) (2011). 
43 USPTO, Report on the Prior User Rights Defense, at 7 (Jan. 2012), 
http://www.uspto.gov/aia_implementation/20120113-pur_report.pdf (explaining 
that to assert the defense, the prior user must establish that the “relevant 
activities occurred more than one year before the earlier of (1) the filing date of 
the patent application or (2) the date of public disclosure by the patentee during 
the patentee’s grace period.”). 
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transferred except as part of a good faith transfer of the entire 
entity or of the particular line of business.44 In the event of such a 
transfer, the acquiring party may not expand use of the subject 
matter entitled to the defense beyond the original geographic site 
of the “prior use.”45 Further, a special limited exemption is 
provided for universities: the prior use defense cannot be used 
against universities or university technology transfer 
organizations.46  
 
C.  Prior Art Expansion and the Modified One-year Grace Period 
 
Whether an invention is sufficiently novel to receive patent 
protection depends on the state of the art in the field. Prior art 
under the AIA is any information available to the public before the 
time at which the inventor files a patent application.47 Submitted 
applications are vetted by an examiner at the USPTO against art in 
the relevant field for patentability, novelty, and nonobviousness.48 
If these and other criteria are met, a patent should issue for an 
invention that was not claimed, taught, or made obvious by the 
prior art. Otherwise, a patent will not issue or, if improperly issued, 
will be invalid. Accordingly, inventors often survey the prior art 
before committing to patent prosecution—a costly effort.49 A 
change to the prior art system could seriously impact prosecution 
costs and the likelihood of obtaining a patent.  
44 Id. 
45 Id. 
46 H.R. 1249 § 5. The university exception does not apply “if any of the 
activities required to reduce to practice the subject matter of the claimed 
invention could not have been undertaken using funds provided by the Federal 
Government.” 35 U.S.C. § 273(e)(5)(B). 
47 Under the AIA, prior art can take the form of a publication, patent, patent 
application, sale, or other public knowledge, use, or offer for sale related to the 
invention. See 35 U.S.C. § 102(a)(1). 
48 Patent applications are considered for applicable subject matter, novelty 
and nonobviousness under 35 U.S.C. §§ 101, 102, and 103, respectively.  
49 One notable practitioner prices patent searches at $1200-$2400, and 
overall prosecution costs between $5,000 and $15,000. See Gene Quinn, The 
Cost of Obtaining a Patent in the U.S, IPWATCHDOG (Jan. 28, 2011), 
http://www.ipwatchdog.com/2011/01/28/the-cost-of-obtaining-
patent/id=14668/. 
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 Comporting with Congress’s intent to harmonize the new 
FITF system with foreign systems, the AIA makes significant 
changes to the prior art element. Under the new 35 U.S.C.  
§ 102(a), the pool of prior art now includes any public use, sale, or 
other disclosure of the invention that renders it “otherwise 
available to the public,” measured back from the effective filing 
date—in the U.S. or a foreign country—rather than the date of 
invention.50 Novelty and nonobviousness will both be determined 
as of the filing date.51  
The new § 102(a) poses multiple challenges for applicants. 
First, the expanded international pool of potential prior art means 
that applicants must vet their inventions against a wider collection 
of information that could be material to patentability.52 For a 
patent to issue, the claimed invention must survive this information 
and any other related art before the examiner.  
The phrase “or otherwise available to the public” in § 102(a)(1) 
further complicates the scope of prior art. Observers have 
expressed confusion over its meaning,53 and question whether the 
phrase modifies the preceding “on sale” category—meaning that 
public sales, but not secret sales (or unpublished pending 
50 Orlando Lopez, The Prior Art Expansion Under the AIA, LEXOLOGY 
(Sep. 18, 2012), http://www.lexology.com/library/detail.aspx?g=6e2a1f97-213e-
42ef-ab22-3e3141f1faa3 (“No longer is the date of invention important — the 
important date now is the effective filing date. This change introduces a game-
changing race to the patent office where the first to file wins.”). 
51 See, e.g., Jay Pattumudo, The Scope of Prior Art by Others Under AIA 
and a Comparison with European and Japanese Patent Law. PATENT BARISTAS 
(May 9, 2013), http://www.patentbaristas.com/archives/2013/05/09/the-scope-
of-prior-art-by-others-under-aia-and-a-comparison-with-european-and-japanese-
patent-law-what-every-scientist-and-corporate-executive-needs-to-know. 
52 Lopez, supra note 50.  
53 See USPTO, Examination Guidelines for Implementing the First Inventor 
to File Provisions of the Leahy-Smith America Invents Act (discussion of Public 
Comment 13), 77 Fed. Reg. 11059 (Feb. 14, 2013), 
https://www.federalregister.gov/articles/2013/02/14/2013-03450/examination-
guidelines-for-implementing-the-first-inventor-to-file-provisions-of-the-leahy-
smith#p-238; Pier D. DeRoo & Michael J. Flibbert, Does the AIA Require 
Public Availability for “On Sale” Prior Art?, BLOOMBERG LAW REPORTS, Mar. 
19, 2012, available at http://www.finnegan.com/resources/articles/ 
articlesdetail.aspx?news=b78c8ba4-db29-48da-b1ba-ec2119083300. 
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applications), continue to be prior art—or stands alone, casting all 
sales activity as potential prior art.54  
As an additional consequence of the shift to FITF, inventors 
can no longer “swear back” past a prior art reference. Under the 
first-to-invent system, an inventor could prove, by sworn affidavit, 
an invention date preceding that of a prior art reference.55 Patent 
prosecutors no longer have this strategic tool to help them prove 
original inventorship.56 
Section 102(b) defines the exceptions to prior art under  
§ 102(a). Previously, inventors enjoyed a one-year grace period, 
dated from the filing date, that foreclosed the specter of prior art in 
which the claimed invention was published or patented in any 
country, or in public use or on sale in the United States.57 The new 
§ 102(b)(1) expands the grace period to include disclosures of the 
invention—or subject matter thereof—by the inventor, a joint 
inventor, or one who obtained the information from the inventor.58  
The modifications to the grace period have generated 
considerable confusion.59 Some practitioners interpret the statute to 
create a “first-to-publish” system whereby publication defeats all 
subsequent third-party prior art.60 Under the USPTO’s proposed 
rules of interpretation, however, only those third-party disclosures 
that are identical or “substantially identical” to the inventor’s 
54 See id. See also Dennis Crouch, Did the AIA Eliminate Secret Prior Art? 
PATENTLYO (Oct. 10, 2012), http://www.patentlyo.com/patent/2012/ 
10/did-the-aia-eliminate-secret-prior-art.html; Matthew R. Osenga, America 
Invents Act—Secret Prior Art, INVENTIVESTEP (March 11, 2013, 2:20 PM), 
http://inventivestep.net/2013/03/11/america-invents-act-secret-prior-art/. 
55 Lopez, supra note 50.  
56 See Id. 
57 For an excellent side-by-side comparison pre-AIA and AIA provisions, 
see Comparison Of Selected Sections Of Pre-AIA and AIA U.S. Patent Law, 
INTELLECTUAL PROPERTY OWNERS ASS’N (Oct. 19, 2011), 
http://www.wilmerhale.com/files/upload/IPO_AIA_Chart.pdf. 
58 35 U.S.C § 102(b)(1)(b) (2011). 
59 See, e.g., Gene Quinn, Defending the USPTO interpretation of the new 
grace period, IPWATCHDOG (Sep. 9, 2012), http://www.ipwatchdog.com/2012/ 
09/09/defending-the-uspto-interpretation-of-the-new-grace-period/id=27903. 
60 See, e.g., Letter from Univ. of Cal. Office of Gen. Counsel to Office of 
Patent Legal Admin. (Oct. 4, 2012), available at http://www.uspto.gov/ 
patents/law/comments/uc_20121004.pdf. 
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initial disclosure will not be counted as prior art.61 Any subsequent 
disclosure that contains even insubstantial changes from the 
original may still count as prior art.62  
Finally, the AIA allows parties to a joint development 
agreement to remove one another’s prior art from consideration 
when seeking a patent.63 Under this rule, a nonprofit engaged in a 
joint development agreement could file a patent application 
without fearing prior art in the form of another partner’s previous 
application. This provision was included to promote joint research 
activities consistent with the Cooperative Research and 
Technology Enhancement (CREATE) Act of 2004.64 
These changes have significant implications for nonprofit 
research organizations. Researchers typically present their work 
numerous times at lab meetings and public forums culminating in 
the publication of an article on their research in an academic 
journal. Whether and when an invention is publicly disclosed 
greatly affects patentability, and nonprofits seeking to protect 
intellectual property must be thoughtful with respect to disclosures. 
Changes to the prior art and the one-year grace period add 
complexity to these considerations. 
These changes also affect patent prosecution. Because of the 
changes to prior art, nonprofits may need to perform due diligence 
on a larger pool of prior art. The resource demands of these 
61 Manual of Patent Examining Procedure (MPEP) § 2112, available at 
http://www.uspto.gov/web/offices/pac/mpep/s2112.html. 
62 See Arpita Battacharyya, Ph.D. and Eric P. Raciti, The Not-So-Amazing 
Grace Period Under the AIA, CIPA JOURNAL (Sep. 2012), 
http://www.finnegan.com/resources/articles/articlesdetail.aspx?news=4acad2aa-
4430-4d87-a197-3a202ac17c5b. 
63 35 U.S.C. § 102(c) (2011). 
64 See AIA 35 U.S.C. § 102(b)(2) (2011), available at 
http://www.govtrack.us/congress/bills/112/hr1249/text. See also Robert A. 
Armitage, Understanding the America Invents Act and its Implications for 
Patenting, 40 AIPLA Q.J. 1, 24–26 (2012) (“the Cooperative Research and 
Technology Enhancement (CREATE) Act of 2004 completed pre-AIA § 103. It 
sought to extend “co-worker” benefits of the AIPA to research collaborators by 
treating patent filings under joint research agreements as though they had been 
commonly assigned. The aggregate result of the pre-AIA amendments to § 103 
was that…the AIP A/CREATE Act changes followed as a new § 103(c).” 
(internal citations omitted)). 
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broader prior art searches could affect some nonprofits’ patenting 
decisions.  
 
D.  Third-Party Challenge System 
 
Prior to implementation of the AIA, the ex parte nature of 
patent applications meant that third parties were generally 
excluded from the application and review processes. However, a 
narrow exception allowed third parties to submit prior art in 
connection with a pending application, but not to comment upon, 
explain, or argue about the submission.65 The procedure was 
designed to improve the quality of issuances by augmenting the 
examiner’s prior art search, but it was rarely practiced.66 The AIA 
encourages expanded third-party prior art submissions by allowing 
third parties who submit prior art to concisely describe the 
relevance of the submitted art.67 
In addition to improving the quality of patents granted and 
shortening the examination period, the third party submission 
65 37 C.F.R. § 1.99 (2011). 
66 LANDERS, supra note 5, at 27. 
67 35 U.S.C. § 122(e)(2) (2011) (“Any third party may submit for 
consideration and inclusion in the record of a patent application, any patent, 
published patent application, or other printed publication of potential relevance 
to the examination of the application (provided that certain requirements are 
met) within the later of either six months from the challenged application’s 
publication or from the USPTO’s first rejection of any claim in the 
application.”). See also Preissuance Submissions by Third Parties, 
AIARULEMAKING.COM,Ihttp://www.aiarulemaking.com/rulemaking-topics/ 
group-2/third-party-submission-prior-art-patent-application.phpi(“Another 
change benefitting third parties is the extended time period that such 
submissions will be accepted. This time period will be the earlier of: 1) the date 
of a notice of allowance, or 2) the later of six months after the date of 
publication or the date of a first Office action on the merits.”); USPTO, Press 
Release 12-60: USPTO Encourages Third Parties to Participate in Review of 
Pending Patent Applications, USPTO.GOV (Sep. 20, 2012), 
http://www.uspto.gov/news/pr/2012/12-60.jsp (“[T]he submission by third 
parties of prior art . . . allows the USPTO to tap directly into the U.S. innovation 
community. Submissions provide a fuller, more exhaustive scope of materials 
for examiners to review in determining the novelty of a given application. This 
new mechanism will help ensure that truly novel, useful, and non-obvious 
innovations obtain the intellectual property protection they deserve”). 
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system allows parties, for a small fee,68 to anonymously or openly 
object to a patent’s issuance. Patent applicants thus must consider 
strategies to defend against third-party submissions and identify 
those parties as potential competitors, licensees, or partners.69  
 
E.  Derivation Proceedings and Post-Grant Review 
 
In conjunction with the move to FITF, and in an attempt to 
improve administrative alternatives to litigation, the AIA revises 
the means by which one challenges a patent’s validity. Previously, 
the USPTO Board of Patent Appeals and Interferences conducted 
interference proceedings—to ascertain priority of inventorship —
and patent reexamination procedures in both ex parte and inter 
partes formats. These proceedings, and the changes to the system 
under the AIA, will be examined in turn.  
Under the first-to-invent system, a third party could challenge a 
pending patent application or unexpired patent on the grounds that 
the patentee was not the first to invent. If the claimed patents in 
dispute met certain requirements, a panel of administrative judges 
would conduct an interference proceeding to assess the evidence 
(without discovery) and arguments of the parties. Interferences 
were considered a cost-effective alternative to patent litigation,70 
though the mean cost of an interference proceeding has been 
68 $180 per ten documents submitted. See Changes To Implement the 
Preissuance Submissions by Third Parties Provision of the Leahy-Smith 
America Invents Act, 77 F.R. 3, 453 (Jan. 5 2012) (to be codified at 37 C.F.R. 
Part 1), http://www.gpo.gov/fdsys/pkg/FR-2012-01-05/pdf/2011-33811.pdf. See 
also USPTO Third Party Preissuance Submission under CFR 1.290 Instructions 
for Paper Filing, available at http://www.uspto.gov/forms/ 
3prsubmission_instructions.pdf (last visited April 5, 2013). 
69 See, e.g., Proposed New Rules Under AIA to Affect Third Party 
Submissions of Prior Art, BRINKS, HOFER, GILSON & LIONE (May 31, 2012), 
http://www.brinkshofer.com/news_events/3406-proposed-new-rules-under-aia-
affect-third-party-submissions-prior-art. 
70 One estimate puts the average costs of a patent litigation at roughly 
$2.5M, dependent on the amount in controversy and the type of technology 
involved. American Intellectual Property Law Association, Report  
of the Economic Survey, 2011, IPISC (2013), available at 
http://www.patentinsurance.com/iprisk/aipla-survey/. 
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estimated at over $650,00071—likely a prohibitive figure for 
nonprofits.72 Although interferences will no longer be conducted 
under the AIA, derivation proceedings will now determine whether 
the first filer derived the invention from the petitioning party and 
thus ascertain priority and inventorship.73   
A number of post-grant proceedings have defined the USPTO’s 
role in adjudicating patent disputes.74 Prior to implementation of 
the AIA, a party challenging the validity of a patent outside of 
litigation could request ex parte or inter partes reexamination by 
the USPTO.75 In a significant revision of the post-grant challenge 
system, the AIA eliminates inter partes reexamination, replaces it 
with post-grant review and inter partes review, and creates 
supplemental examinations. These changes were designed to 
increase the availability of cost-effective alternatives to patent 
litigation.76  
Comporting with the AIA’s goal of producing better patents 
and rectifying improper issuances, the post-grant and inter partes 
review procedures are designed to expedite challenges.77 Limited 
71 Herbert D. Hart, III, An Interference: What, When, And How Much Does 
It Cost?, AM. BAR ASS’N SECTION OF INTELLECTUAL PROP. LAW, 9 (Apr. 2007), 
http://www.mcandrews-ip.com/files/article/Hart%20-%20Interference%20What 
%20When%20How%20Much%20%20ABA%20IPL%2013%20Apr%2007%20
Logo.pdf. 
72 This observation is based on comments from our survey respondents as 
well as outside sources. See, e.g., Gene Quinn, Reform Doing Away with 
Interference Proceedings & First to Invent, IPWATCHDOG (Mar. 26, 2010), 
http://www.ipwatchdog.com/2010/03/26/reform-doing-away-with-interference-
proceedings-first-to-invent/id=9859/ (“With that cost [$($650,000]), not many 
independent inventors or small businesses are going to be able to foot that 
bill.”). 
73 See LANDERS, supra note 5, at 56. 
74 It should be noted that the USPTO does not adjudicate infringement 
actions or breach of contract related to a patent. These are matters for the federal 
and state courts.  
75 Inter Partes Review, AM. INVENTS ACT, 
http://www.aiarulemaking.com/rulemaking-topics/group-2/inter-partes-
review.php (last visited Feb. 6, 2014).  
76 Id. 
77 See Lawrence A. Stahl and Donald H. Heckenberg, The Scope and 
Ramifications of the New Post-Grant and Inter Partes Review Proceedings 
at the USPTO. FITZPATRICKCELLA.COM, http://www.fitzpatrickcella.com/ 
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discovery and a guaranteed hearing in post-grant review permit an 
initial opportunity to address troublesome patents, while the 
second window (nine months or more post-issuance) of inter partes 
review protects patentees by narrowing the grounds for review and 
types of evidence accepted.78  
Finally, the AIA creates supplemental examinations, which 
enable patent owners to assess the strength of their patents—and 
preempt third-party challenge or ex parte reexamination—by 
submitting additional information that allows the USPTO to 
“consider, reconsider, or correct information believed to be 
relevant to the patent.”79 These examinations also provide patent 
owners with “amnesty” against charges of inequitable conduct—
information provided in a supplemental examination cannot be 
used to render a patent unenforceable.80  
 
III. THE SURVEY: DATA ANALYSIS 
 
To assess the AIA’s impact, realized or anticipated, on 
nonprofit bioscience and global health research, we surveyed in-
house (n = 10) and outside attorneys (n = 7) representing 
organizations throughout the region. The participating 
organizations varied greatly in terms of age, size, available 
resources, stated goals, and means of achieving those goals. For 
example, while some institutions conduct basic research and seek 
DB6EDC/assets/files/News/Fitz_PTO_1_4_8.pdf, (last accessed Feb. 7, 2014).  
78 LANDERS, supra note 5, at 57. 
79 35 U.S.C. § 257(a) (2011). 
80 See LANDERS, supra note 5, at 54. Inequitable conduct is an affirmative 
defense to a claim of patent infringement. Essentially, the defense asserts that 
the patent is unenforceable due to the patentee’s fraudulent withholding of, or 
submission of, material information to the USPTO during prosecution “but for 
which” a patent would not have issued. See Therasense, Inc. v. Becton, 
Dickinson & Co., 649 F.3d 1276, 1287 (Fed. Cir. 2011) (“To prevail on the 
defense of inequitable conduct, the accused infringer must prove that the 
applicant misrepresented or omitted material information with the specific intent 
to deceive the PTO. The accused infringer must prove both elements—intent 
and materiality—by clear and convincing evidence. If the accused infringer 
meets its burden, then the district court must weigh the equities to determine 
whether the applicant's conduct before the PTO warrants rendering the entire 
patent unenforceable.”). 
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licensing agreements to commercially develop promising 
technologies, others determine how to best allocate grants to 
further specific research or initiatives. Some larger entities with 
greater resources have internal technology transfer and 
commercialization departments that are not present in smaller 
entities.81  
In this section, we discuss the qualitative responses of in-house 
and outside counsel to our survey. For each area of the law, we 
include a brief summary of the changes to that area, followed by 
the questions we posed (in bold) and the responses by each group. 
Please note that we sought global perspectives on the new law, as 
distinct from the specific concerns of any particular organization. 
Our data set represents cumulative, qualitative responses, and does 
not represent the views of any particular organization.  
 
A.  First-Inventor-To-File 
 
The AIA converts the patent priority system from first-to- 
invent to FITF. We first surveyed respondents on the transition to 
FITF and its effects on nonprofit R&D and patent practices:  
 
1. In your opinion, will FITF impact nonprofit organizations’ 
research and development? Why or why not? 
 
In-house counsel generally answered that FITF will probably 
not impact nonprofit R&D for two reasons. First, research 
scientists at nonprofit organizations are generally not focused on 
patenting their inventions; rather, they are driven by a desire to 
expand knowledge and make beneficial discoveries. Because most 
nonprofit research is funded by grants, scientists focus mainly on 
publishing and writing grant proposals.  
Second, when nonprofit organizations decide to protect their 
biotechnology inventions, internal practices already follow the 
international first-to-file and absolute novelty standards. For this 
reason, if research produces a seemingly novel innovation, the 
81 The respondents to our survey pointed out that even well-funded private 
nonprofits possess far fewer resources than a large, state-funded research 
university. 
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nonprofit organization has typically filed a provisional application 
to secure a patent placeholder before any disclosure is made. For 
most respondents, then, adherence to best practices will mitigate 
the effects of FITF on nonprofit research and development. 
However, some in-house respondents noted that the AIA might 
impact research and development by increasing pressure to “race 
to the USPTO” to file cover sheet provisional applications. The 
problem with this scenario is that the provisional application, 
produced under pressure and probably with a bare minimum of 
data to support the disclosure, will not satisfy the first-paragraph 
requirements of § 11282 (written description83 and enablement84). 
82 The disclosure requirements under 35 U.S.C. § 112, ¶ 1 include written 
description, enablement, and best mode. Specifically, that provision states that 
the specification “shall contain a written description of the invention, and of the 
manner and process of making and using it, in such full, clear, concise, and 
exact terms as to enable any person skilled in the art to which it pertains [. . .] to 
make and use the same, and shall set forth the best mode contemplated by the 
inventor or joint inventor of carrying out his invention.” 35 U.S.C. § 112 (2011) 
(emphasis added).  
83 The written description requirement has several policy objectives. In 
Ariad, the court held that there is a separate written description and enablement 
requirement under 35 U.S.C. § 112, first paragraph. Ariad Pharmaceuticals, Inc. 
v. Eli Lilly and Co., 598 F.3d 1336, 1341 (Fed. Cir. 2010) (en banc). The written 
description requirement has several policy objectives. “[T]he ‘essential goal’ of 
the description of the invention requirement is to clearly convey the information 
that an applicant has invented the subject matter which is claimed.” In re Barker, 
559 F.2d 588, 592 n.4 (C.C.P.A.CCPA 1977). Another objective is to put the 
public in possession of what the applicant claims as the invention. See Regents 
of the Univ. of Cal. v. Eli Lilly, 119 F.3d 1559, 1566, (Fed. Cir. 1997), cert. 
denied, 523 U.S. 1089 (1998). The written description requirement implements 
the principle that a patent must describe the technology that is sought to be 
patented; the requirement serves both to satisfy the inventor’s obligation to 
disclose the technologic knowledge upon which the patent is based, and to 
demonstrate that the patentee was in possession of the invention that is claimed. 
Capon v. Eshhar, 418 F.3d 1349, 1357 (Fed. Cir. 2005). 
84 To satisfy the enablement requirement under 35 U.S.C. § 112, first 
paragraph, a patent application must provide sufficient disclosure to enable a 
person skilled in the art to make and use the claimed invention. One skilled in 
the art would be enabled to practice the claimed invention if it would not require 
undue experimentation to make and use the claimed invention and the claims are 
not of undue breadth in view of the scope of the disclosure provided by the 
specification. The Wands factors are considered by courts when determining 
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As such, some anticipate that nonprofit organizations will respond 
to FITF by tightening internal procedures to make sure that 
scientists do not disclose before filing and that the application is as 
strong as possible. 
Outside counsel generally agreed with the in-house position, 
suggesting that FITF will not impact nonprofit organizations’ 
research because those organizations already follow international 
standards. The grace period changes generate some uncertainty, 
discussed infra, but the best practice for nonprofit organizations 
remains to file early and often.  
Outside counsel gave four reasons for this filing practice: first, 
when considering the costs of patenting, which are low relative to 
the high potential value of patent protection, inventors are advised 
to err on the side of filing on the invention at its early stage of 
development.85 Second, they pointed out that novelty and 
obviousness requirements incentivize early filing in order to 
establish priority over prior art that may render the subject matter 
anticipated or obvious.86 Finally, outside counsel stressed that the 
formerly common practice of “swearing behind” a prior art 
reference to prove an earlier date of invention would no longer be 
an option under the FITF. One caveat that outside counsel 
highlighted was that the pressure to be the first to file may affect 
the quality and scope of the disclosure made. That is, the 
disclosure may not support future claims that would have benefited 
from the earlier priority date. The practice of filing early and often 
could potentially increase the frequency of applications and affect 
whether there is sufficient evidence to support a determination does not satisfy 
the enablement requirement and whether any necessary experimentation is 
“undue.” In re Wands, 858 F.2d 731, 737 (Fed. Cir. 1988). 
85 See, e.g., Christopher A. Cotropia, The Folly of Early Filing in Patent 
Law, 61 HASTINGS L.J. 65, 69 (2009). 
86 See Lee A. Hollaar, LEGAL PROTECTION OF DIGITAL INFORMATION IN 
CHAPTER 4: AN OVERVIEW OF PATENTS: VI—ANTICIPATION AND OBVIOUSNESS 
(2002), available at http://digital-law-online.info/lpdi1.0/treatise57.html (last 
accessed Feb. 7, 2014) (“If a claim reads on a single item of prior art – a printed 
publication or a product – then that item of prior art “anticipates” the claim must 
be rejected under Section 102 […]Section 103 bars a claim if it is obvious based 
on a combination of two or more items of prior art, or differs in an obvious way 
from an item of prior art.”) 
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resource allocation; thus, the next question we asked was the 
following:  
 
2. In your opinion, will the FITF system affect when provisional 
or nonprovisional applications are filed? Why or why not? 
 
In-house counsel generally felt that the FITF system would not 
affect when nonprofit organizations file applications for three 
reasons. First, they recalled that nonprofits have long practiced 
under international first-to-file standards. Second, frequent filing 
practices have been in place to account for ongoing disclosures by 
their scientists. Third, budget constraints mean that the number of 
applications filed is unlikely to increase.  
A few respondents again suggested that the “race to file” under 
FITF might diminish the value of provisional applications. As 
noted supra, there is a danger that quickly filed provisional 
applications might not satisfy § 112. Under pre-AIA law, it was 
standard practice for biotechnology inventors to record a plan for a 
project and use that as the date of conception.87 The inventor 
would then work diligently to make and test the invention before 
filing an application.88 However, under the AIA, this approach 
creates a risk that the first inventor is blocked from obtaining a 
patent by another’s patent application or publication.89 Therefore, a 
rush to produce and file an application before the invention’s 
reduction to practice may be the new standard. 
Even if the inventor is the first to file, the application will be 
vulnerable to rejection by the PTO—or, if a patent issues, to later 
validity challenges—if the initial disclosure does not sufficiently 
describe the invention to show that the inventor was actually in 
possession of the invention at the time of application.90 Thus, for 
an inventor to claim the benefit of a provisional filing date, the 
87 George Yu, How the First-To-File Provisions of the America Invents Act 
Will Affect Biotechnology, SCHIFFHARDIN (Feb. 1, 2012), 
http://www.schiffhardin.com/File%20Library/Publications%20(File%20Based)/
PDF/yu_sfdj_020112.pdf. 
88 Id. 
89 Id. 
90 Id. 
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provisional application must fully support the claims included in 
the nonprovisional patent application. The claims must be 
described and enabled by the provisional application, and an FITF-
induced rush to file might compromise the patentability and value 
of an invention. 
Outside counsel were split on this question. Some believed that 
nonprofit organizations would change patent filing practices due to 
FITF for three reasons. First, nonprofit organizations might 
increase the number of provisional applications that are filed in 
order to secure patent protection in the United States, even though 
foreign protection would be jeopardized under the international 
absolute novelty standard.91 The one-year grace period should 
continue to give U.S. applicants time to prepare and file their 
applications after disclosure. Consequently, some outside counsel 
predicted an increase in early provisional applications filed 
immediately after disclosure. 
Second, the need for selectivity and resource management 
under FITF will be exacerbated by the generally poor economic 
environment, which may further depress nonprofits’ ability to file 
early and often. Although the filing fee for a provisional 
application in the United States is relatively low,92 nonprofit 
91 See European Patent Office, European Patent Convention Art. 54(2) 
available at http://www.epo.org/law-practice/legal-
texts/html/epc/2013/e/ar54.html (“The state of the art shall be held to comprise 
everything made available to the public by means of a written or oral 
description, by use, or in any other way, before the date of filing of the European 
patent application.”). 
92 A provisional application filing fee is $250 ($125 for small entities), 
compared with $1,250 for a nonprovisional application. Under 35 U.S.C. § 
41(h)(1), fees charged under 35 U.S.C. § 41(a), (b), and (d)(1) shall be reduced 
by 50 percent with respect to their application to any small business concern as 
defined under § 3 of the Small Business Act, and to any independent inventor or 
nonprofit organization as defined in regulations issued by the Director. 35 
U.S.C. § 41. The reduced fees include patent application filing fees including the 
basic filing fee, search fee, examination fee, application size fee, and excess 
claims fees (37 C.F.R. § 1.16) extension of time, revival, and appeal fees (37 
C.F.R. § 1.17), patent issue fees (37 C.F.R. § 1.18), statutory disclaimer fee (37 
C.F.R. § 1.20(d)), and maintenance fees on patents (37 C.F.R. § 1.20). See 
USPTO, MPEP § 509.02, available at http://www.uspto.gov/web/offices/ 
pac/mpep. 
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organizations still have nominal budgets that restrict the number of 
provisional applications filed.93 Because biotechnology patents are 
generally protected worldwide, and because nonprofit 
organizations have restricted budgets, these organizations will need 
to exercise even more care when deciding where to file for a 
patent.94 Finally, the number, type, and timing of patent 
applications filed depend on the nonprofit organizations’ 
intellectual property strategy. As of this writing, two pressing 
questions for patent applicants are whether to file a provisional 
application before March 16, 2013 and whether to switch an 
existing provisional application to nonprovisional status before 
March 16, 2013.95  
Other outside counsel believe that FITF will not have an 
impact on when nonprofits file for two reasons, both related to 
existing best practices. First, the current practice of filing under an 
international first-to-file regime suggests that disclosure 
management will not change much in response to FITF. Second, 
investing resources to file a supportive provisional application that 
satisfies § 112 should be the primary concern, even though 
frequent filing is almost equally important. To recall, only those 
93 For a complete list of filing, prosecution and maintenance fees, see 
USPTO, Fee Schedule, http://www.uspto.gov/web/offices/ac/qs/ope/ 
fee010114.htm (last revised Jan. 16, 2014).  
94 The U.S. 2011 Global Patent & IP Trends Indicator: An in-depth look at 
the foreign filing strategies of U.S. patent owners, INNOVIA (2011), 
http://de.inovia.com/news/110228-inovia-Global-Patent-IP-Trends.jsp. A 2011 
survey of nearly 150 companies, universities, and nonprofits that assessed the 
impact economic conditions on global IP strategy and outlook reported that 
nearly 60 percent of respondents are working on a reduced IP budget and many 
are taking further steps to reduce patent costs. Forty-five percent of those 
surveyed did not file into Japan in 2010 because of the high cost and low cost-
to-benefit ratio; that is, the patent owner had to justify the success rate of getting 
a patent in Japan, (approximately 20 percent) in light of the high filing cost. Due 
to such high costs, companies tend to file in China for foreign protection, 
reserving only extremely valuable filings for Japanese foreign jurisdiction.  
95 This means that if the provisional application was converted after the 
March 16 changeover date, any claim directed to disclosure that was not 
supported by the original first-to-invent provisional application will be treated 
under the FITF regime. See Leonid Kravets, First-to-File Patent Law Is 
Imminent, But What Will It Mean?, TECHCRUNCH (Apr. 8, 2013), 
http://techcrunch.com/2013/02/16/first-to-file-a-primer/.  
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aspects of an invention that are supported by the provisional 
disclosure will receive the benefit of the provisional priority date.96  
 
B.  Prior Commercial Use and the University Exception 
 
The AIA expands the prior commercial use defense to include 
all manner of patented inventions.97 This defense to a claim of 
infringement derives from commercial use of the invention prior to 
another’s patenting the invention,98 and is an option for securing 
continued use without fear of infringement.99 Under the AIA, 
instead of obtaining patent protection and disclosing the invention, 
a user may practice the invention secretly and, if challenged, rely 
on the prior commercial use defense to avoid liability.100 With this 
in mind, we asked: 
 
1. In your opinion, will nonprofit organizations benefit from the 
prior commercial use defense? Why or why not? 
 
In-house counsel mostly answered that nonprofits would not 
benefit from the commercial use defense because they are not 
generally involved in “commercial” activity. Further, nonprofits 
are infrequent targets for patent litigation due to their public profile 
and relative lack of money. Hence, a defense to infringement 
claims is unlikely to be of special interest to nonprofits. However, 
one respondent opined that the AIA introduces uncertainty by 
failing to specifically define “commercial process.” Though the 
statutory language and legislative history support a broad 
interpretation of the term,101 the specific activities that will be 
96 Timothy D. Casey & Juan C. Quiroz, What Innovators Need to Know–
and Need to Do–Under the America Invents Act, AMERICAN INNOVATORS FOR 
PATENT REFORM, at 4 (Jan. 2012), available at http://www.aminn.org/files/ 
WhitePaper-AmericaInventsAct-Jan2012-2.pdf. 
97 Id. 
98 35 U.S.C. § 273(a) (2011). 
99 Michael Dixon, The Sweeping Changes of the 2011 America Invents Act, 
WESTLAW, at 7 (2012), http://www.mofo.com/files/uploads/images/120206-
patents-21st-century.pdf. 
100 Id. 
101 Craig R. Smith, The Prior Use Defense Under AIA, LAW 360 (Nov. 9, 
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protected under this provision are uncertain and will likely be 
determined through litigation.  
A minority of outside counsel believed that the prior 
commercial use defense’s university exception may benefit 
nonprofit organizations when a university was involved in the 
research project or if the nonprofit was determined to have 
“university” status. Some also expected that where the public was 
the intended beneficiary of the prior use, as generally occurs at 
nonprofit research organizations like hospitals, the use will be 
deemed commercial for the purpose of obtaining the defense. 
The defense may also benefit nonprofits in the context of 
licensing—if the defense is transferrable to a licensee, patents may 
hold much greater value. Although the general rule is that the prior 
user defense is personal and cannot be transferred in isolation, it 
can be transferred as part of a larger good faith sale of the business 
or line of business, which may include licenses.102 How this 
applies in the licensing context remains to be seen. The attorneys 
also stressed that the prior user defense cannot be raised against 
universities.  
In response to concerns that the prior commercial use defense 
would stifle innovation at universities, the legislature enacted the 
university exception, preventing assertion of the prior use defense 
2011), http://www.lalaw.com/news-events/publications/upload/THE-PRIOR-
ART-DEFENSE-UNDER-AIA.pdf. 35 U.S.C. § 273(c)—entitled “Additional 
commercial uses”—sets forth two qualifying commercial uses: (1) use or 
marketing during a premarketing regulatory review period, and (2) nonprofit 
laboratory use by universities, hospitals, and other nonprofit entities. The 
legislative history suggests that commercial use may begin early in the use or 
development of the technology. 35 U.S.C. § 273(c) (2011). Senator Leahy, one 
of the co-sponsors of the patent reform bill, stated that the prior use defenses 
vests when “innovative technology is first put into continuous internal use in the 
business of an innovator’s enterprise with the objective of making a commercial 
product.” See S. Doc. No. S5427 Senate (Sept. 8, 2011), available at 
http://www.gpo.gov/fdsys/pkg/CREC-2011-09-08/pdf/CREC-2011-09-08-
senate.pdf. 
102 See Peter A. Nieves, A Stronger Patent Infringement Defense Due To 
Prior User Rights, SHEEHAN PHINNEY (Feb. 21, 2013) http://www.sheehan.com/ 
publications/good-company-newsletter/A-Stronger-Patent-Infringement-
Defense-Due-To-Prior-User-Rights.aspx. 
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against a university or its technology transfer organization.103 
However, the limiting language104 of the exception appears to 
revive the defense against patents for inventions related to stem 
cell research or human cloning, as well as any other research areas 
that are prohibited from receiving federal funding.105 
 
2. In your opinion, how will the university exception benefit or 
disadvantage nonprofit organizations? 
 
In-house counsel were split on this question. Some believed 
that the exception only covers universities and not other nonprofit 
organizations, which accounted for the bulk of our respondents. 
However, others believed that this protection may be available to 
non-university nonprofit organizations or licensees that foster 
collaborative relationships with universities. The scope of the 
exception will probably be determined by litigation. In-house 
respondents’ responses were limited, which may reflect a lack of 
familiarity with this AIA provision, the infrequency of patent 
litigation involving nonprofits, or both.  
Outside counsel largely anticipate that the exception will 
103 USPTO, REPORT ON THE PRIOR USER DEFENSE, 37 (2012), available at 
http://www.uspto.gov/aia_implementation/20120113-pur_report.pdf. 
104 This exception does not apply “if any of the activities required to 
reduce to practice the subject matter of the claimed invention could not have 
been undertaken using funds provided by the Federal Government.” 35 U.S.C.  
§ 273(e)(5)(B) (2011). 
105 Patents owned by universities or technology transfer organizations are 
subject to an exception from the expanded prior user defense, but this exception 
does not apply “if any of the activities required to reduce to practice the subject 
matter of the claimed invention could not have been undertaken using funds 
provided by the federal government.” See Brad D. Pedersen, US Patent Reform: 
What Really Changes , PATTERSON THUENTE IP, (Sept. 23, 2011), available at 
http://www.ptslaw.com/PatentReformSummaryOverviewWhitepaper.pdf. The 
National Institute of Health federal grant guidelines prohibit research funding 
for human embryonic stem cells (hESCs), the derivation of stem cells from 
human embryos, or using hESCs derived from other sources, including somatic 
cell nuclear transfer, parthenogenesis, and/or in vitro fertilization embryos 
created for research purposes. See NIH Grants Policy Statement, NAT’L INST. OF 
HEALTH (Oct. 2012), http://grants.nih.gov/grants/policy/nihgps_2012/ 
nihgps_ch4ch4index.htm. 
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benefit both university and non-university nonprofits by 
incentivizing relationships with universities. However, a few 
expect no impact because the defense is rarely invoked and has 
seen little to no successful assertion. The USPTO Report on the 
Prior User Rights Defense supports this expectation, noting that 
while the Federal Circuit has decided thousands of appeals on 
almost every imaginable patent doctrine, the Court has yet to 
address prior user rights.106 
 
C.  Prior Art Expansion and the Modified One-Year Grace Period 
 
The AIA expands the pool of prior art both geographically and 
categorically. Prior art now includes knowledge, use, or any 
activities rendering the invention “otherwise available to the 
public” in the United States or any other country. Further, the 
inventor’s one-year grace period is modified. We wondered 
whether navigating a larger pool of prior art might affect resource-
limited nonprofits and whether the changes to the grace period held 
any special significance.  
 
1. In your opinion, how will these changes affect nonprofit patent 
strategies? 
 
In-house counsel answered that the AIA’s prior art provisions 
would not affect patent strategies for three reasons. First, 
nonprofits have historically operated from an international patent 
perspective in order to maximize the reach of beneficial 
innovations. Protecting intellectual property in multiple markets 
widens the potential pool of licensees and often enables the 
nonprofit to effect change where it matters. For example, an 
organization dedicated to fighting malaria in subtropical countries 
106 Report on the Prior User Defense, USPTO, at 31 (2012), 
http://www.uspto.gov/aia_implementation/20120113-pur_report.pdf (concluding 
that while prior user rights have been available in the United States since 1999 
for business method patents, “only one case has been reported in which this 
defense has been raised,” and the court in that case did not reach the issue 
because the defense was untimely raised). 
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might limit its reach if it only pursued patent protection in the 
United States. If an invention addresses a problem that exists in 
both developed and developing countries, the nonprofit may 
leverage patent protection into a licensing agreement whereby the 
licensee reaps profits in advanced economies in exchange for 
discounting or giving away the developed product in poorer 
economies. Comprehensive patent protection across markets thus 
encourages mutually advantageous licensing opportunities, so 
international practices are favored. 
Second, nonprofits rarely have the resources to conduct 
comprehensive prior art searches. In-house attorneys in this 
industry typically cannot focus solely on intellectual property, and 
a quick survey of publicly available patent databases will not 
suffice. Even subscriptions to patent-listing periodicals107 may be 
prohibitively expensive, and the likelihood of as-yet-unpublished 
prior art cannot be assessed. A caveat exists where the innovation 
in question is highly valuable and exists in a tightly defined field of 
technology. In such circumstances, the likelihood of competition 
and licensing potentials are both high, and the nonprofit may spend 
more aggressively to obtain the patent. 
However, given the nature of the technology, particularly 
where the research concerns rare diseases, few commercial 
“blockbusters” are anticipated. More often, attorneys must look to 
cheaper sources of information. For example, the investigators at 
these institutions often work in narrow fields and have a 
comprehensive understanding of the relevant art. Given the largely 
collaborative nature of the academic community, the likelihood 
that unanticipated prior art exists is fairly low. Furthermore, the 
academic journals that publish research advances act as a novelty  
 
107 Subscription-based commercial patent databases such as Delphion, 
MicroPatent, and LexisNexis provide updated lists of available patents, 
applications, and other information relevant to the state of a given patent area. 
The costs range widely from $181-361/mo (Delphion), to $7500/yr 
(MicroPatent) (note: these prices reflect only a couple of a wide range of patent 
prosecution products). See Delphion Subscription Comparison Overview, 
DELPHION, http://www.delphion.com/products/research/products-compare2 (last 
accessed Feb. 6, 2014); PatentWeb, MICROPATENT, http://www.micropat.com/0/ 
products_pw9809.html (last accessed Feb. 6, 2014).  
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filter; because journals seek to publish only novel findings, 
publication is a strong indicator of patentable novelty. 
Third, due to licensing practices, nonprofits rarely need to 
expend significant resources on prior art searches. Most licensing 
deals are negotiated in the year following a provisional filing, and 
if an exclusive license is given, the licensee assumes responsibility 
for prosecuting the patent.108 Whether the nonprofit or a licensee 
pursues the patent, it is common practice to file a PCT 
application109 and allow an authorized patent assessor to provide 
an initial determination on patentability.110 For these reasons, 
particularly under an FITF regime, nonprofits will continue to file 
early and often. 
Outside counsel largely echoed these points, but emphasized 
that clients should be educated as to changes in the law, such as the 
end of “swearing back” to defeat a prior art reference under the old 
system.111 Filing prior to disclosure was also stressed, though, as 
discussed previously, the race to file might have the unintended 
effect of increasing the number of “coversheet provisional”  
 
 
108 The nature of the patent and the market largely determine whether a 
given license is exclusive or nonexclusive. See University Technology Transfer: 
Questions and Answers, UNIVERSITY OF CALIFORNIA TECHNOLOGY TRANSFER, 
http://www.ucop.edu/ott/faculty/tech.html#6 (last accessed Mar. 30, 2013). 
(“Patents which are broad in scope and can be used in multiple industries, or 
patents that they are so basic that they form the building blocks for new 
technologies are most likely to be licensed non-exclusively [while universities] 
most frequently will grant exclusive licenses to patents that require significant 
private investment to reach the marketplace or are so embryonic that exclusivity 
is necessary to induce the investment needed to determine utility.”). 
109 Under the Patent Cooperation Treaty of 1970 (PCT), inventors in 
signatory states can file a unified PCT application to obtain a priority filing date 
in all other signatory states. Subsequent additional measures to meet 
jurisdictional requirements must follow to obtain actual patent protection. See 
James R. Cartiglia, The Patent Cooperation Treaty: A Rational Approach to 
International Patent Filing, 76 J. PAT. & TRADEMARK OFF. SOC'Y 261, 262-63 
(1994).  
110 Inventions claimed in PCT applications are vetted by an authorized 
“International Searching Authority” (ISA) that issues to the applicant a written 
opinion on the patentability of the invention. See id. at 268. 
111 Lopez, supra note 50.  
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applications, which risk failing the written description and 
enablement requirements of § 112. 112 
Only one outside attorney suggested that the expanded field of 
prior art might depress the value of licensing agreements. Where 
comprehensive due diligence has not been completed, the 
expanded pool of prior art may represent increased uncertainty as 
to the novelty and nonobviousness of the invention. Therefore, 
licensees may attempt to shift this risk onto licensors with 
contingency clauses addressing the possibility of claim rejection by 
the USPTO or of a successful validity challenge. The nonprofit’s 
response might include devoting more resources to prior art 
searches or grouping riskier or less-attractive patents with safer or 
more attractive patents in combined licensing agreements. 
Going forward, challenges and questions remain with regard to 
prior art. How “otherwise available to the public” is interpreted by 
the MPEP113 and by the courts may impact the way that nonprofit 
research organizations share their work. If secret sales or offers to 
sell are no longer prior art, patent-holders may be incentivized to 
sell their inventions more freely, using non-disclosure language in 
contracts as a shield. Additionally, the AIA allows unknown prior 
art—given the benefit of an initial filing date despite only 
becoming public in a USPTO publication eighteen months later—
to be used in assessing both the novelty and nonobviousness of a 
claimed invention.114 A larger pool of such art may affect patent 
valuations or prosecution decisions. 
However, there are hints as to what prior art might look like 
under the AIA. In response to public commentary, the USPTO 
suggested that “otherwise available to the public” would likely be 
112 As mentioned supra, “coversheet” or “manuscript” provisionals refer to 
applications that contain only a written description and relevant drawings of the 
invention, as well as identifying information for the inventor. Such applications 
are generally submitted shortly after invention to secure a provisional filing date. 
See USPTO, PROVISIONAL APPLICATION FOR PATENT (Feb. 2011), 
http://www.uspto.gov/patents/resources/types/provapp.jsp.  
113 The USPTO directs its examiners on applying the law to patent 
applications in the MPEP, available at http://www.uspto.gov/web/offices/ 
pac/mpep. 
114 Robert A. Armitage, Understanding the America Invents Act and its 
Implications for Patenting, 40 AIPLA Q.J. 1, 27. 
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assessed under the Federal Circuit’s test: whether the material was 
“available to the extent that persons interested and ordinarily 
skilled in the subject matter of the art, exercising reasonable 
diligence, can locate it.”115 
Further, comments of the AIA drafters suggest that secret sales 
were not intended to become prior art.116 Taking this history into 
account, the USPTO has stated that it will interpret “the ‘or 
otherwise available to the public’ residual clause of the AIA's 35 
U.S.C. § 102(a)(1) as indicating that secret sale or use activity does 
not qualify as prior art.”117 This issue may still be resolved by the 
courts, however, and is likely to be tested. 
 
2. Do you anticipate that the grace period rule will affect the 
collaborative nature of research and the quality of the resulting 
work? Why or why not? 
 
In-house counsel generally responded that collaboration would 
not be affected, although few supporting details were provided. As 
a group, they seemed less familiar with this change than did 
outside practitioners. This may have been due to the fact that in-
house counsel practitioners do not specialize in patent law, or to 
115 See USPTO, Examination Guidelines for Implementing the First 
Inventor to File Provisions of the Leahy-Smith America Invents Act (Feb. 14, 
2013), https://www.federalregister.gov/articles/2013/02/14/2013-03450/ 
examination-guidelines-for-implementing-the-first-inventor-to-file-provisions-
of-the-leahy-smith (citing Voter Verified, Inc. v. Premier Election Solutions, 
Inc., 687 F.3d 1374, 1380 (Fed. Cir. 2012) and Bruckelmyer v. Ground Heaters, 
Inc.,445 F.3d 1374, 1378 (Fed. Cir. 2006)). 
116 See C.R., Senate, 23 CONG. REC. S5431 (daily ed. Sept. 8, 2011) 
(statement of Sen. Kyl: “public uses and sales are prior art only if they make the 
invention available to the public.”). See also 157 CONG. REC. S1496-S1497 
(daily ed. Mar. 9, 2011) (statement of Sen. Leahy: § 102(a)(1) “was drafted in 
part to do away with precedent under current law that private offers for sale or 
private uses or secret processes practiced in the United States that result in a 
product or service that is then made public may be deemed patent-defeating 
prior art.”).  
117 USPTO, Examination Guidelines for Implementing the First Inventor 
to File Provisions of the Leahy-Smith America Invents Act, 78 Fed. Reg. 11060 
(Feb. 14, 2013), http://www.uspto.gov/aia_implementation/FITF_Final_ 
Guidelines_FR_2-14-2013.pdf. 
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inherent ambiguities in the statute. Patent education efforts within 
the institution were identified as an asset, but the ability to 
implement such efforts was resource-dependent. Larger nonprofits 
had more highly developed patent education and communication 
schemes, while entities with lesser means gave fewer seminars and 
presentations to their employees. However, all in-house counsel 
framed the question as one of strategic relevance: where freely 
disseminating an invention better serves the goals of a research 
organization than would a patent, the need for educating inventors 
on the patent system diminishes. Likewise, where recouping costs 
is not a concern—e.g., for low-overhead technologies like 
antibodies—, adherence to best patent practices is accordingly less 
important. 
This may be changing, however. Counsel for one large entity 
stated that potential faculty members increasingly inquire as to the 
organization’s technology transfer practices. The possible reasons 
for this interest were not speculated, but it is sensible for 
researchers to consider how conducive the institution’s policies are 
to conducting compelling research and securing scarce funding. 
Patent infrastructure may be viewed as a limiting diversion of 
resources; alternatively, a researcher’s proprietary interest might be 
a motivating factor. It is common for investigators to maintain a 
stake in the innovations their lab produces, and a patent may 
function as a revenue stream or as an asset for investigator to “spin 
off” to independently sell or license.118 
In sum, in-house counsel did not give detailed responses as to 
whether the grace period changes would affect collaboration, but 
the generally felt that any impact would be negligible. Familiarity 
with international practices, including early filing and absolute 
novelty requirements, is expected to mitigate any growing pains. 
One in-house attorney stated that good collaborations are directed 
by intellectual property concerns; however, it is unclear how well 
the changes to the grace period are truly understood, and a few of 
in-house attorneys assessed the grace period as a false safety net.  
Outside counsel answered that collaboration could well be 
118 See, e.g., Science and Policy Introduction: The New Spin on Spin-offs, 
ORG. FOR ECONOMIC COOPERATION AND DEV., http://www.oecd.org/science/sci-
tech/introductionthenewspinonspin-offs.htm (last visited Apr. 8, 2013).  
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detrimentally affected by a poor understanding of the new rules. 
Ambiguity in the grace period provision language has drawn 
criticism, including an official comment by the Washington State 
Patent Lawyers Association to the USPTO regarding the 
difficulties of the new grace period provision to the USPTO.119 An 
ill-timed disclosure may compromise the value of the invention 
and stifle an advance. On the other hand, the fear of such 
disclosures may hinder collaborative efforts. Thus, outside 
practitioners recommended educating clients about the law as 
described in subsection 3 infra.  
Even where inventors firmly understand the law, outside 
counsel cited other areas of concern. One suggested that the need 
for quick reactions by inventors under the AIA might render 
collaborations more difficult, but acknowledged that this issue 
might be mitigated by familiarity with international practices. 
119 E-mail and attached letter from Amanda Carmany-Rampey, Ph.D., 
Chair, Patent Office Rules and Practices Committee, Washington State Patent 
Law Association, to USPTO Undersecretary Kappos, Attention: Mary C. Till, 
Senior Legal Advisor, Office of Patent Legal Administration, Office of the 
Deputy Commissioner for Patent Examination Policy (Oct. 5, 2012), available 
at http://www.uspto.gov/patents/law/comments/wspla_20121005-guid.pdf (“The 
legislative history of the AIA indicates [intent] to protect inventors who 
publically disclose their invention before filing a patent application by providing 
a grace period. The proposed examination guidelines, however, practicably 
eliminate this grace period for any third-party disclosures that are not verbatim 
reproductions of a prior disclosure by the inventor or joint inventor . . . . The 
interpretation of 35 U.S.C. § 102(b)(1)(88B) and 35 U.S.C. § 102(b)(2)(88B) 
promulgated in the proposed examination guidelines unduly limits the 
applicability of the prior art exceptions with respect to subsequent, non-derived, 
third-party disclosures, such that the exceptions are practically meaningless. The 
proposed examination guidelines do not cite any authority for this interpretation; 
to the contrary, the proposed examination guidelines are directly in conflict with 
the legislative history of the AIA. Further, the proposed examination guidelines 
do not provide any examples of instances where two independent disclosures by 
an inventor and a subsequent third party would not have "insubstantial changes" 
or "trivial or obvious variations." Without further guidance, it is reasonable to 
interpret the provisions of 35 U.S.C. § 102(b)(1)(88B) and 35 U.S.C. § 
102(b)(2)(88B) as being applicable only in instances of verbatim reproduction, a 
scenario likely already provided for under 35 U.S.C. § 102(b)(1)(A) and 35 
U.S.C. § 102(b)(2)(A). Thus, it is unclear when, if ever, the prior art exceptions 
under 35 U.S.C. § 102(b)(1)(88B) and 35 U.S.C. § 102(b)(2)(88B) would apply 
under the proposed examination guidelines.”). 
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Another perspective was that while the AIA incentivizes joint 
research collaborations by permitting collaborators to discount 
prior art by the other party,120 the new disclosure rules place added 
importance on careful drafting and negotiation of collaboration 
agreements.  
We noted that our in-house respondents represented a broad 
spectrum of nonprofits in terms of size, goals, and resources. 
Given the resource balancing act and other challenges imposed 
upon nonprofits by the AIA, we wondered whether outside counsel 
would provide different advice to nonprofits along this spectrum. 
 
3. In light of these changes, how would you advise nonprofits at 
various stages of their development? 
 
Despite the inquiry, outside counsel did not address nonprofits 
of any particular size or resource set. Rather, they simply stressed 
adherence to best practices, including careful management of 
disclosures, and noted the tension between filing early and often 
and obtaining sufficient data to satisfy § 112—though strong 
filings were prioritized over early filings. With respect to the FITF 
system, counsel reiterated their comments as described previously. 
The only emergent theme was an emphasis that under an 
international filing system, pre-AIA practices, such as filing in a 
foreign patent office before disclosing in the United States, are 
now obsolete with respect to U.S. priority.  
The lack of clarity surrounding the new prior art categories and 
changes to the grace period also prompted the attorneys to stress 
intra-organizational communication and schedule-keeping so that 
any disclosure that is “available to the public” is preceded by a 
provisional application. The danger of manuscript provisional 
failing § 112 was reiterated, and filing early under FITF should be 
secondary to filing a strong provisional. A continuation that claims 
the priority date of the provisional application should be 
continually updated so that the “original disclosure” supports all 
relevant advances in a final nonprovisional application. Further, 
any reliance on the one-year grace period was discouraged. If the 
120 35 U.S.C. § 102(c) (2011). 
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entity is involved in or seeking a collaboration, careful negotiation 
and drafting of intellectual property terms, particularly regarding 
disclosures and filing procedures, will be of paramount 
importance. A comprehensive understanding of the relevant arts is 
ideal, though this is a difficult goal to achieve.  
Finally, outside practitioners emphasized the need to keep good 
notebooks and records of invention. Careful note taking allows 
inventors to track mistakes, avoid duplicative experimentation, and 
accurately record both results and inventions.121 Moreover, while 
interference proceedings are abolished by the AIA, good records 
remain invaluable in derivation proceedings. Respondents 
recommended that upon invention, an inventor’s notebook should 
be signed and dated by a witness who understands both the 
invention and the state of the art. Of course, the reality is that 
notebooks will always be primarily for scientific purposes. 
Adherence to the best practices, from patent-conscious record-
keeping to properly managing disclosures, will be difficult to 
ensure. 
 
4. In your opinion, do your clients clearly understand what 
constitutes prior art and “disclosures” under the new law? If 
not, would you suggest taking steps to make this clearer? 
 
While some in-house attorneys had previously stated that their 
scientists were well versed in the basics of patent law, outside 
practitioners felt differently. Several stated that new prior art 
system, and not FITF, represented the most significant change 
under the AIA. They recommended education programs at the 
nonprofit level to explain the law—one attorney suggested 
teaching programs for attorneys in CLE seminars—with a specific 
emphasis on three points related to prior art and the grace period.  
121 The Stanford University Office of Technology Licensing provides a list 
of recommended best practices, including making sketches and written 
description upon invention, temporally consecutive entries, and comprehensive 
descriptions of experiments, equipment, and results. See Suggestions for 
Keeping Laboratory Notebooks, STANFORD UNIV. OFFICE OF TECH. LICENSING, 
http://otl.stanford.edu/inventors/resources/inventors_labnotebooks.html (last 
visited April 2, 2013).  
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First, “disclosures” have grown in complexity. Public 
disclosure can take myriad forms, including academic poster 
sessions, written abstracts for research talks, PowerPoint slides, 
and journal publications, all common features of academic 
research. One attorney speculated that a web posting regarding a 
future presentation might qualify. New media, such as blogs, 
personal websites, and online academic journals should also factor 
into disclosure considerations. Even patent-savvy innovators may 
be caught by surprise, as some online journals now publish 
uncorrected proofs of submitted articles before notice of formal 
publication to the author.122 
Second, outside counsel cautioned that the grace period 
changes are nuanced. As stated supra, the grace period does not 
create a “first to publish” system where publishing prior to filing 
defeats all subsequent art. Though the USPTO’s recently-released 
final examination guidelines adopt a softer stance towards grace 
period disclosures than had previously been discussed,123 the 
122 Online in less time, NATURE NEUROSCIENCE, Aug. 2001 at 767, 
available at http://www.nature.com/neuro/journal/v4/n8/pdf/nn0801_767a.pdf. 
123 In previous iterations of proposed examination guidelines, the USPTO 
had suggested that disclosures that differed only in trivial or insubstantial ways 
from the applicant’s initial disclosure would still become prior art against the 
inventor. However, this stance has been changed in response to public comment. 
See USPTO, EXAMINATION GUIDELINES FOR IMPLEMENTING THE FIRST 
INVENTOR TO FILE PROVISIONS OF THE LEAHY-SMITH AMERICA INVENTS ACT, 
F.R. 03450 (Office of the Federal Register Feb. 14, 2013), available at 
https://www.federalregister.gov/articles/2013/02/14/2013-03450/examination-
guidelines-for-implementing-the-first-inventor-to-file-provisions-of-the-leahy-
smith (“[T]hese examination guidelines also clarify, in response to the public 
comment, that there is no requirement that the mode of disclosure by an inventor 
or joint inventor (e.g., publication, public use, sale activity) be the same as the 
mode of disclosure of the intervening disclosure, (e.g., inventor discloses his 
invention at a trade show and also does not require the intervening disclosure is 
in a peer-reviewed journal). Additionally, there is no requirement that the 
disclosure by the inventor or a joint inventor be a verbatim or ipsissimis verbis 
disclosure of the intervening disclosure. In addition, these examination 
guidelines also clarify that in order for the exception based on a previous public 
disclosure of subject matter by the inventor or a joint inventor to apply. These 
guidelines also clarify that the exception applies to subject matter of the 
intervening disclosure that is simply a more general description of the subject 
matter previously publicly disclosed by the inventor or a joint inventor. . . . [I]f 
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governing rules for which disclosures will fall within the grace 
period and which will vitiate its protections remain to be seen. 
Third, and crucially, the AIA grace period only extends to 
disclosures made in the United States.124 Publications available in 
other jurisdictions immediately risk becoming prior art against the 
inventor, and the global interests of the research organization must 
factor into careful management of disclosures. Therefore, not all 
public disclosures are per se protected by the grace period and 
inventors must proceed carefully in making disclosures and in 
seeking patents. Early filing, awareness of the grace period rules, 
and general education regarding the AIA were stressed as critical 
adaptations to the new law. 
To facilitate this education, the best practice is open 
communication between the nonprofit and a patent specialist. 
Presentations or training by an attorney can teach guiding 
principles to researchers, administration, and leadership and 
explain the role that patents can play in fulfilling the organization’s 
mission. Within an organization, vertical channels of 
communication can promote early identification of valuable 
innovations and careful recording habits. The attorneys 
commented, however, that motivating researchers to implement 
such practices, rather than focusing solely on publishing, would be 
difficult. 
 
D.  Third-Party Challenge System 
 
subject matter of the intervening disclosure is simply a more general description 
of the subject matter previously publicly disclosed by the inventor or a joint 
inventor, the exception in AIA 35 U.S.C. 102(b)(1)(B) applies to such subject 
matter of the intervening disclosure. The specific comments on this issue are 
also discussed in greater detail in the Responses to Specific Comments section.” 
(See Comment 31 and Response). 
124 A handful of other jurisdictions, including Canada and Australia, 
independently provide a one-year grace period. For all intents and purposes, 
U.S. filings receive grace period protection only in the United States. See Bill 
Herman, The America Invents Act: practical upcoming implications—part II, 
LEXOLOGY.COM (Feb. 4, 2013), http://www.lexology.com/library/ 
detail.aspx?g=3ab2164f-bb67-430d-b96b-5874f5db74be.  
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The AIA enhances the ability for third party challengers to 
challenge a pending patent application by submitting prior art to 
the USPTO. Unlike pre-AIA law, the challenger can now include a 
concise description of the prior art to direct the examiner. We 
wondered whether nonprofits might react to an increased 
likelihood of challenge, or whether they were now more likely to 
participate in the challenge system.  
 
1. In your opinion, will the third-party submission changes to the 
AIA affect resource allocation in the patent process and the 
resulting quality of the patented invention? Why or why not? 
 
All counsel unanimously responded that while the challenge 
system might make for better patents, it would have no effect on 
how nonprofits allocated their resources or the quality of 
inventions produced. Only one in-house attorney mentioned having 
been involved with a challenge under the old system; the 
overwhelming message was that nonprofits are rarely subjected to 
such challenges and would not put any further resources into 
shoring up a given invention or application simply due to this 
provision of the AIA.  
As with the prior art expansion, some outside attorneys noted 
that the increased likelihood of third-party challenges might affect 
patent valuations by potential licensees. Again, the nonprofit 
response may be providing more data or performing more due 
diligence than might have occurred prior to the AIA. Any such 
effort is likely to be made easier in the collaborative and open 
context of academic science, but still may constitute a burden for 
nonprofits. Shifting the perspective, we asked whether nonprofits 
were more likely to initiate or participate in third party challenges 
under the AIA:  
 
2. Do you feel that nonprofits are more likely to participate in 
third party challenges? If so, how does this change your 
counsel? 
 
In-house counsel generally answered that while the third party 
challenge system is more conducive to participation by nonprofit 
organizations, expectations of participation were mixed. Generally 
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speaking, these organizations are not as adversarial regarding their 
work as their for-profit counterparts and are less likely to challenge 
patents. Two attorneys stated that anything over the cost of an in-
house provisional application would be disfavored, making third-
party challenges unlikely.  
Others responded from a risk-analysis perspective, stating that 
nonprofits may be involved when a licensee challenges a 
competitor’s application. However, all attorneys agreed that 
participation will only occur if it furthers the nonprofit’s goals. In 
the reverse situation, a higher likelihood of challenges against a 
nonprofit would probably encourage the nonprofit to license or 
cross-license with the challenger in order to diffuse the challenge 
and foreclose rejection by the USPTO or invalidation in litigation.  
Outside counsel gave similar answers. A minority did suggest 
that, of all the new pre- or post-grant challenge options, the third-
party challenge system represented the cheapest and most 
attractive option for nonprofits to participate. Moreover, the ability 
to participate anonymously may prove an attractive feature for 
image-conscious nonprofits.  
However, this is balanced against the fact that even minimal 
added costs may preclude participation by resource-limited 
nonprofits. All outside counsel felt that challenges will not be a 
priority for nonprofits and that any participation will be tied to 
challenges by licensees. An exception may occur when the 
nonprofit is heavily invested in a particular area of technology and 
must, by necessity, influence the patent field.  
One attorney cautioned that third party challenges are strategic 
gambles. Should the challenger fail, the submitted prior art will 
only strengthen the patent at issue and compromise any other 
avenue for challenge on the same grounds. Therefore, potential 
challenges should be evaluated against the strength of the patent as 
well as challenger’s perceived chances in a post-grant proceeding 
or in litigation.  
Since the challenge system was opened in an attempt to induce 
more participation, we wondered, whether a given nonprofit acts as 
a challenger or a defensive party, if the challenge system under the 
AIA is more equitable than it was previously. 
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3. In your opinion, does the AIA provide a more equitable 
challenge system for nonprofits? If so, why? 
 
This question was not ideally drafted, as it elicited responses 
about the entire pre- and post-grant challenge system rather than 
specifically about third-party pre-issuance challenges. These 
responses are addressed in the next section. To the extent that 
third-party challenges were mentioned, all responding attorneys 
felt that this mechanism was somewhat more equitable to resource-
challenged entities than the old system, but that on the whole, the 
AIA had not made the challenge system more equitable. We then 
proceeded to ask respondents specifically about the post-grant 
proceedings: 
 
E.  Derivation Proceedings and Post-Grant Validity Challenges 
 
1. The AIA has introduces four new challenge proceedings, each 
with distinct features. Do you anticipate whether any, or all, of 
the new proceedings will be attractive or helpful to nonprofits? 
If so, why? 
 
In-house counsel did not seem familiar with each of the new 
provisions, but the overwhelming consensus was that, despite the 
AIA’s efforts to open up the challenge system, nonprofit 
organizations are still extremely unlikely to participate in any of 
the various challenges. Licensing practices and other 
considerations mean that nonprofits are unlikely to invalidate the 
patents of others. Furthermore, the costs of post-grant proceedings, 
while lower than litigation, are still prohibitive for nonprofits. 
Universities also highlighted the difficulty in convincing the state 
attorney general’s office that such proceedings would be a worthy 
expenditure of taxpayer monies. 
A few respondents mentioned that post-grant review, allowing 
a wider scope of prior art discovery, seemed like the most 
attractive post-issuance option but emphasized that participation 
was very unlikely. Derivations, on the other hand, could be helpful 
where collaborations go wrong or, alternatively, records of 
collaboration might help in a derivation proceeding against a third 
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party. One respondent made the illuminating point that while 
nonprofits, particularly those working on “neglected” diseases, are 
not often subject to suit in the current environment, changing 
global economic circumstances may change this dynamic.  
Specifically, those entities focused on treating tropical or 
subtropical diseases, or afflictions not often considered in the 
major pharmaceutical markets of Japan, Europe, and the United 
States, could assume a more significant market role as countries 
like China, India, and Brazil grow in population and economic 
standing. In that event, market participants will scrutinize 
heretofore less-valuable patents more closely and a deeper 
understanding of the challenge system will be required of the 
holder. 
Outside counsel echoed their in-house counterparts, 
emphasizing that since nonprofits are rarely the targets of patent 
litigation, they are not especially concerned with litigation 
alternatives. Post-grant review and inter partes review were 
considered too expensive and typically occur so late in the timeline 
of an invention that the nonprofit is no longer directly involved—
licensees are much more likely to use these offensive weapons. 
One attorney pointed out that in the rare event that a nonprofit’s 
patent is subjected to post-grant review, the nonprofit need not 
spend on defense as they would in litigation; rather, the USPTO 
conducts the proceeding with a presumption of validity.125  
From a defensive perspective, outside attorneys felt that the 
new challenge system favored large corporations over nonprofit 
inventors. Wealthy businesses can more easily afford the fees and, 
thanks to the bifurcation of inter partes reexamination into post-
grant review and inter partes review, now enjoy two opportunities 
to challenge the patents of smaller entities. Respondents thus felt 
that the new challenge system tilts in favor of large entities, is less 
equitable for nonprofits, and is unlikely to produce better patents.  
Finally, outside attorneys cited supplemental examinations as a 
helpful way to prevent any future litigation and to clean up patent 
prosecution history. Whether the costs will be borne by a licensee 
or by the nonprofit remains to be seen. As with the changes to prior 
125 35 U.S.C. § 282 (2011). 
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art, the one-year grace period, and the third party challenge system, 
a few outside attorneys speculated that the uncertainty created 
might reflect on patent valuations and licensing deals. The actual 
effect of this uncertainty is unclear and may take years of litigation 
to provide a proper foundation for risk assessment.  
 
CONCLUSION 
 
Because nonprofit bioscience organizations have unique goals, 
incentives, and challenges, we designed our survey to address 
those aspects of the AIA that we felt were likely to pose special 
challenges to them, either due to their collaborative and open-
source nature or to the resource restrictions under which they often 
operate. Our results met some of our expectations, defied others, 
and added a great degree of nuance to our understanding of the 
AIA and of the challenges faced by our respondents. 
The AIA reshaped the face of patent law in the United States 
by transitioning the priority system from first-to-invent to FITF. 
We expected this transition to a high-pace FITF system to further 
burden resource-limited nonprofits; we discovered, however, that 
the transition’s effect was minimal because nonprofit organizations 
(due to licensing practices and the international nature of their 
guiding principles) were already practicing under the international 
first-to-file standard. Outside counsel warned, however, that a race 
to file could result in more manuscript provisional applications 
being filed and failing to satisfy the patentability requirements of  
§ 112. 
In-house counsel further did not expect the expanded prior 
commercial use defense to impact the generally non-commercial 
nature of nonprofits’ research activities, but future litigation 
regarding the definition of a “commercial activity” could add 
relevance to this defense. Outside counsel foresaw that the defense, 
as well as the university exception, could be beneficial to licensees 
and may encourage collaboration with universities or other 
academic nonprofits that may fall into that category.  
Likewise, in-house counsel did not expect much impact due to 
the changes regarding prior art and the one-year grace period. First, 
in-house counsel expect that, in narrow and highly specialized 
fields, their own inventors are effectively experts in the state of the 
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art, meaning that while prior art may “expand” for inventors in 
other sectors, scientists used to publishing, patenting, and 
collaborating on an international level would not experience any 
change due to an expanded field of prior art. Furthermore, 
international absolute novelty practices have meant that filing early 
is standard procedure, and to the extent that the U.S. one-year 
period is taken advantage of, in-house counsel did not foresee any 
specific change. Again, outside counsel urged greater resources be 
put toward understanding the new laws. They recommended 
education programs to relay to nonprofit innovators both the new 
definition of “public disclosures”—specifically, the ramifications 
of the “or otherwise available to the public” language in  
§ 102(a)(1)—and the important nuances of the one-year grace 
period. Whether a subsequent disclosure of the invention is 
afforded the grace period or vitiates it is as yet unclear. For 
scientists whose general goal is to share their research in a variety 
of forums, proper disclosure management and careful collaboration 
practices require careful consideration under the AIA. One outside 
attorney pointed out that while nonprofit innovators may feel well-
prepared for the AIA’s changes, the story may not be the same for 
potential licensees, who might consider the prior art and grace 
period rules as risks to patentability (e.g., whether the original 
provisional has satisfied the § 112 requirements and supports a 
final nonprovisional, or whether priority, novelty, or 
nonobviousness becomes an issue under the new rules) that 
depress the value of licenses. These complexities are not likely to 
be sorted out in litigation for several years and may require an 
adjustment period.  
The AIA also introduced new ways in which the validity of 
patents can be challenged both before and after issuance, yet 
neither in-house nor outside counsel felt that third party challenges, 
derivation proceedings, ex parte reexamination, post-grant review, 
or inter partes review were particularly pertinent to nonprofits. 
Nonprofit organizations do not challenge patents; rather, they are 
interested in publishing, obtaining funding, and finding licensees 
for their technology. Prior to the AIA, nonprofits rarely engaged in 
any form of challenge because (a) they typically license out 
enforcement rights to a wealthier commercial partner with better 
incentives, and (b) they are rarely targeted for challenge or 
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litigation due to their narrow technological focus, lack of 
commercial presence, and the public relations issues that a plaintiff 
might expect in suing a nonprofit research organization. Although 
the AIA attempts to encourage a more thorough vetting process by 
expanding a variety of avenues for pre- and post-grant challenge, 
our respondents expect no reaction from nonprofits. Challenged 
entities are likely to seek licenses or cross-licenses with 
challengers rather than risk invalidation, and nonprofits remain 
extremely unlikely to engage as challengers. At this time, the 
challenge system is most likely to affect nonprofits only indirectly, 
with commercial partners and potential licensees reacting to the 
uncertainties of an expanded challenge system. 
In sum, our survey indicates that most effects of the AIA on 
nonprofit science research and global health are likely to be 
secondary, creating risks and uncertainties for commercial 
licensing partners that may affect the ability of nonprofits to 
accomplish their individual missions both in the United States and 
around the world. We hope that this survey of nonprofit actors in 
the Pacific Northwest provokes thought and provides guidance to 
innovators—particularly with respect to disclosures—and patent 
practitioners in this and other communities. Science will only 
effect as much change as can be funded, and with the global 
economy a state of flux, understanding all means—including 
patents—for enabling laboratory advances, product development, 
and effective delivery is indispensable to fulfilling nonprofits’ 
scientific and humanitarian missions. 
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